Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Accelovance’s Stephen Trevisan And Robert deGroof On China’s Clinical Research Landscape: An Interview With PharmAsia News (Part 1 of 2)

This article was originally published in PharmAsia News

Executive Summary

Accelovance CEO Stephen Trevisan and Chief Scientific Officer Robert deGroof recently spoke with PharmAsia News about the evolving landscape for conducting clinical trials in China. Accelovance, based in Rockville, Md., has 10 clinical sites in the U.S. and a wholly owned enterprise in China with offices in Beijing and Shanghai to provide International Conference on Harmonization-good clinical practices compliant clinical trials.

You may also be interested in...



Chinese Health Care Reform: Market Opportunities And Challenges

China's renewed emphasis on reforming its health care system is creating both opportunities and challenges for foreign manufacturers doing business there, according to speakers at AdvaMed's 2008 MedTech Conference in Washington, D.C

Chinese Health Care Reform: Market Opportunities And Challenges

China's renewed emphasis on reforming its health care system is creating both opportunities and challenges for foreign manufacturers doing business there, according to speakers at AdvaMed's 2008 MedTech Conference in Washington, D.C

Accelovance’s Stephen Trevisan And Robert deGroof On China’s Clinical Research Landscape: An Interview With PharmAsia News (Part 2 of 2)  

[Editor's Note: This is part two of a two-part interview. Part one appeared in PharmAsia News, May 15, 2008.]

UsernamePublicRestriction

Register

ID1122434

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel